Titan Pharmaceuticals (NASDAQ:TTNP) signed a specialty product distribution agreement with CVS Caremark, a subsidiary of CVS Health, further expanding access to treatment with Probuphine implant, Titan’s novel maintenance treatment for opioid use disorder (OUD) in eligible patients.
“We believe this expansion will enhance the ability of eligible patients suffering from OUD to gain better access to long-term maintenance treatment with Probuphine,” Titan’s chief commercial officer, Dane Hallberg, said in a statement.
Titan’s strategic expansion of its specialty pharmacy network is a key component of its focused commercialization strategy for Probuphine.
Titan expects the majority of Probuphine sales in the U.S. to be through the specialty pharmacy distribution model, where a specialty pharmacy carries inventory, directly handles the subsequent patients’ insurance billing and payment processes, and ships to the healthcare provider as prescribed.
